rhGGF2 protects against cisplatin-induce
β
MariΓ«l P. ter Laak; Frank P.T. Hamers; Cassandra J. Kirk; Willem Hendrik Gispen
π
Article
π
2000
π
John Wiley and Sons
π
English
β 199 KB
π 1 views
In many patients treated with cisplatin a peripheral sensory neuropathy develops. This side-effect is considered dose-limiting, and therefore restricts the total dose of cisplatin that can be administered. Recent in vitro and in vivo studies suggest that recombinant human Glial Growth Factor 2 (rhGG